Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

Core Insights - Amicus Therapeutics reported total revenue of $125.2 million for Q1 2025, reflecting a 15% increase year-over-year at constant exchange rates (CER) [1][5][10] - The company is expanding its portfolio by in-licensing DMX-200, a Phase 3 program for a rare kidney disease, which has significant market potential in the U.S. [1][4] - Amicus is maintaining its 2025 guidance for Galafold, indicating strong underlying demand, while updating guidance for Pombiliti + Opfolda due to accelerating new patient starts in the second half of the year [1][3][9] Financial Performance - Total revenues for Q1 2025 were $125.2 million, with a 15% growth at CER, despite a currency headwind of $1.4 million or 1% [5][10] - Galafold net product sales were $104.2 million, a 5% increase year-over-year, while Pombiliti + Opfolda sales surged by 90% to $21.0 million [6][10] - The company adjusted its total revenue growth guidance for 2025 to 15-22% at CER, with Galafold growth expected at 10-15% and Pombiliti + Opfolda growth revised to 50-65% [9][10] Corporate Developments - Amicus has entered into an exclusive U.S. licensing agreement with Dimerix for DMX-200, enhancing its rare disease portfolio [4][10] - The company anticipates surpassing $1 billion in total sales by 2028, driven by the growth of Galafold and Pombiliti + Opfolda [10][23] - Regulatory approvals for Pombiliti + Opfolda have been granted in Canada and Australia, with expectations for further approvals in Japan and additional reimbursement agreements [10][10]